Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

Assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of lisaftoclax.

Trial Details

NCT ID
NCT04215809
Phase
PHASE1
Sponsor
Ascentage Pharma Group Inc.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Lisaftoclax
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Charlotte, North Carolina, United States|35.22709,-80.84313
  • Canton, Ohio, United States|40.79895,-81.37845

Key Eligibility Criteria

  • ≥18 years of age.
  • Histologically confirmed chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) according to the 2018 international workshop (IW) C…
  • Eastern Cooperative Oncology Group (ECOG) ≤ 2.
  • Patient must have objectively documented evidence of disease progression prior to study entry such as: escalating lymphocytes count with an increas…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →